



PRESS RELEASE

REGULATED INFORMATION

21 February 2019, 07:00 CET

BIOCARTIS TO HOST WEBCAST FOR ANNOUNCEMENT 2018 FINANCIAL RESULTS ON 28 FEBRUARY 2019

Mechelen, Belgium, 21 February 2019 – Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company, today announces that it will host a live webcast on Thursday, 28 February 2019 at 14:00 CET / 13:00 BST (UK) / 08:00 EDT (US) to announce its 2018 results, 2019 outlook and to provide an update on the Company's Idylla™ test menu strategy.

The live webcast can be accessed on the [Biocartis website](#) or by clicking [here](#). To participate in the questions and answers session, please dial in 5-10 minutes prior to the start time by using the numbers below, followed by the confirmation code 1775755. The webcast and conference call will be conducted in English. A replay of the webcast will be available on the [Biocartis investors website](#) shortly after.

Conference call dial-ins:

- United Kingdom (standard international): +44 (0)8445718892
- Belgium, Brussels: +32 (0)24009874
- France, Paris: +33 (0)176700794
- Netherlands, Amsterdam: +31 (0)207143545
- United States, New York: +1 6315107495

Confirmation code: 1775755

----- END -----

More information:

Renate Degrave

Manager Corporate Communications & Investor Relations

e-mail rdegrave@biocartis.com

tel +32 15 631 729

mobile +32 471 53 60 64

[@Biocartis](#) www.linkedin.com/Biocartis

About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology. This area represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer. More information: www.biocartis.com. Press Photo Library available [here](#). Follow us on [Twitter](#): @Biocartis_.

Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis trademark and logo and the Idylla™ trademark and logo are used trademarks owned by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.

Forward-looking statements

This press release may contain forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements speak only as of the date of this press release. Biocartis expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements.